cosentyx article Cosentyx is the first and only fully-human interleukin-17A (IL-17A) antagonist. In the SCALP study, patients with moderate to severe psoriasis lesions of the scalp (n=102) were ...

EAST HANOVER, N.J., Feb. 16, 2018 /PRNewswire/ -- Novartis announced today additional results from the SCULPTURE study showing that two thirds of moderate to severe plaque psoriasis patients treated ...

- Phase IIIb CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx™ (secukinumab) compared to Stelara® (ustekinumab) at Week 16 - In ...

Basel, February 8, 2018 - Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx ® (secukinumab), the first interleukin-17A (IL-17A) inhibitor ...

Novartis AGNVS ended 2017 on a positive note, courtesy of strong performance of psoriasis drug, Cosentyx. Cosentyx achieved multi-blockbuster drug status in 2017 on the back of strong growth in three ...

Eli Lilly’s anti-IL-23 antibody beat placebo at clearing psoriasis symptoms in a phase 3 study, teeing up regulatory filings across the globe. But that’s not all—the drug also outshone Novartis’ ...

The approval was based on data from two phase 3 trials that evaluated the use of Cosentyx in patients 6 to 18 years of age with severe plaque psoriasis who were candidates for systemic therapy. The ...

Novartis International AG / Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show . Processed and transmitted by West Corporation. The ...

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx™ (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes ...

EAST HANOVER, N.J., June 1, 2021 /PRNewswire/ — Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx (R) ...

(RTTNews) - Swiss drug major Novartis AG (NVS) said Friday that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency (EMA) has adopted a positive opinion for ...